GU Cancers 2025 | Real-world outcomes in Germany of EV and pembrolizumab in mUC
Stefanie Zschaebitz, MD, Heidelberg University Hospital, Heidelberg, Germany, gives an overview the results of a retrospective analysis (GUARDIANS) of enfortumab vedotin (EV) plus pembrolizumab in German patients with metastatic urothelial carcinoma (mUC). The analysis found promising efficacy with a high overall response rate and a median progression-free survival of around 13 months. Safety data indicated manageable adverse events, with no new safety concerns, supporting the combination strategy as an effective first-line treatment for mUC. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
